MaxCyte (MXCT) announced it has entered into a strategic platform license, SPL, agreement with Legend Biotech (LEGN), a global leader in cell therapy. Under the terms of the SPL, Legend Biotech obtains a non-exclusive worldwide license to use MaxCyte’s Flow Electroporation technology and ExPERT platform in connection with the research, clinical development and commercialization of cell-based therapeutical products. In return, MaxCyte will be eligible to receive annual licensing fees and milestones from Legend Biotech during clinical development and, upon successful commercialization, is eligible to receive licensing fees and royalties on net sales of licensed products.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MXCT:
- MaxCyte Partners with Legend Biotech for Cell Therapy Advancements
- MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
- BlackRock Acquires Major Stake in MaxCyte
- MaxCyte Q1 Earnings Surge with SPL Program Success
- MaxCyte Files Q1 2024 Financials with SEC